{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/306867117"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "This trial was announced in September 2008.- The ONWARD (Oral Cladribine Added ON To Rebif New Formulation in Patients With Active Relapsing Disease) study: a Phase II placebo-controlled trial designed primarily to evaluate the safety and tolerability of adding cladribine tablets treatment to patients with relapsing forms of MS, who have experienced breakthrough disease while on established interf" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "blogspot.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/124451442"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/306867117"] } } }
